SG10201900648SA - Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide - Google Patents

Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide

Info

Publication number
SG10201900648SA
SG10201900648SA SG10201900648SA SG10201900648SA SG10201900648SA SG 10201900648S A SG10201900648S A SG 10201900648SA SG 10201900648S A SG10201900648S A SG 10201900648SA SG 10201900648S A SG10201900648S A SG 10201900648SA SG 10201900648S A SG10201900648S A SG 10201900648SA
Authority
SG
Singapore
Prior art keywords
triazin
quinolin
imidazo
benzamide
ylmethyl
Prior art date
Application number
SG10201900648SA
Inventor
Elisabete Goncalves
Christin Tauchmann
Shau-Fong Yen
Sudha Vippagunta
Zhixin Zong
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53762251&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201900648S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG10201900648SA publication Critical patent/SG10201900648SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/06—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

The present invention is related to tablets comprising of 2-fluoro-N-methyl-4-[7-(quinolin-6- ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, practices for the production thereof, and uses in the treatment of certain cancers. (Figure 1)
SG10201900648SA 2014-07-25 2015-07-22 Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide SG10201900648SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462028865P 2014-07-25 2014-07-25

Publications (1)

Publication Number Publication Date
SG10201900648SA true SG10201900648SA (en) 2019-02-27

Family

ID=53762251

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201900648SA SG10201900648SA (en) 2014-07-25 2015-07-22 Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
SG11201700147SA SG11201700147SA (en) 2014-07-25 2015-07-22 Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201700147SA SG11201700147SA (en) 2014-07-25 2015-07-22 Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide

Country Status (30)

Country Link
US (4) US10085993B2 (en)
EP (2) EP3172209B1 (en)
JP (3) JP6770946B2 (en)
KR (2) KR102581121B1 (en)
CN (2) CN115364061A (en)
AR (1) AR101286A1 (en)
AU (4) AU2015293539A1 (en)
CA (1) CA2954840A1 (en)
CL (1) CL2017000180A1 (en)
CO (1) CO2017000586A2 (en)
DK (1) DK3172209T3 (en)
EA (2) EA202191301A1 (en)
EC (1) ECSP17011672A (en)
ES (1) ES2857523T3 (en)
FR (1) FR22C1058I2 (en)
GT (1) GT201700007A (en)
HU (2) HUE053346T2 (en)
IL (1) IL250166B (en)
JO (1) JO3618B1 (en)
MX (2) MX2017001177A (en)
MY (1) MY187276A (en)
NZ (1) NZ728089A (en)
PE (1) PE20170523A1 (en)
PH (1) PH12017500121A1 (en)
PL (1) PL3172209T3 (en)
PT (1) PT3172209T (en)
SG (2) SG10201900648SA (en)
SI (1) SI3172209T1 (en)
TW (2) TW202200148A (en)
WO (1) WO2016012963A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013149581A1 (en) 2012-04-03 2013-10-10 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
EA202191301A1 (en) * 2014-07-25 2021-11-30 Новартис Аг COMPOSITION OF TABLETS 2-FLUORO-N-METHYL-4- [7- (QUINOLIN-6-YLMETHYL) IMIDAZO [1,2-b] [1,2,4] TRIAZIN-2-YL] BENZAMIDE
BR112019002007B1 (en) 2016-08-10 2024-01-16 F. Hoffmann-La Roche Ag PHARMACEUTICAL COMPOSITION AND USE OF A PHARMACEUTICAL COMPOSITION
WO2022007752A1 (en) * 2020-07-06 2022-01-13 苏州晶云药物科技股份有限公司 New crystal form of benzamide compound and dihydrochloride thereof, and preparation method therefor
WO2023138492A1 (en) * 2022-01-19 2023-07-27 南京明德新药研发有限公司 Composition of pyrimidine group-containing tricyclic compound, preparation method therefor and use thereof
WO2023249994A1 (en) * 2022-06-22 2023-12-28 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2465565A1 (en) * 2003-06-12 2004-12-12 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
KR20080039876A (en) * 2005-07-22 2008-05-07 미리어드 제네틱스, 인크. High drug load formulations and dosage forms
MY151003A (en) 2005-09-12 2014-03-31 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
CA2563690C (en) * 2006-10-12 2014-10-07 Pharmascience Inc. Pharmaceutical compositions comprising intra- and extra- granular fractions
ES2689444T3 (en) 2006-11-22 2018-11-14 Incyte Holdings Corporation Imidazotriazines and imidazopyrimidines as kinase inhibitors
SI2300455T1 (en) * 2008-05-21 2017-12-29 Incyte Holdings Corporation Salts of 2-fluoro-n-methyl-4-(7-(quinolin-6-yl-methyl)- imidazo(1,2-b)(1,2,4)triazin-2-yl)benzamide and processes related to preparing the same
FI2498756T4 (en) * 2009-11-09 2023-03-22 Tablet formulations of neratinib maleate
EP2574168B9 (en) * 2010-05-21 2016-10-05 Incyte Holdings Corporation Topical formulation for a jak inhibitor
ES2609791T3 (en) 2010-07-06 2017-04-24 Janssen Pharmaceutica, N.V. Formula for diabetes co-therapy treatments
KR20210049187A (en) 2012-08-16 2021-05-04 노파르티스 아게 Combination of pi3k inhibitor and c-met inhibitor
EA202191301A1 (en) * 2014-07-25 2021-11-30 Новартис Аг COMPOSITION OF TABLETS 2-FLUORO-N-METHYL-4- [7- (QUINOLIN-6-YLMETHYL) IMIDAZO [1,2-b] [1,2,4] TRIAZIN-2-YL] BENZAMIDE

Also Published As

Publication number Publication date
US10596178B2 (en) 2020-03-24
MY187276A (en) 2021-09-17
AU2020200912B2 (en) 2021-01-28
SG11201700147SA (en) 2017-02-27
HUE053346T2 (en) 2021-06-28
EA039220B1 (en) 2021-12-20
EA201790259A1 (en) 2017-06-30
KR102581121B1 (en) 2023-09-21
NZ728089A (en) 2024-01-26
AR101286A1 (en) 2016-12-07
IL250166B (en) 2021-01-31
DK3172209T3 (en) 2021-02-22
EP3172209B1 (en) 2020-12-02
KR20170039211A (en) 2017-04-10
CN106714784A (en) 2017-05-24
IL250166A0 (en) 2017-03-30
JP2020114852A (en) 2020-07-30
EP3172209A1 (en) 2017-05-31
KR20230136693A (en) 2023-09-26
JP2017521469A (en) 2017-08-03
US20190015418A1 (en) 2019-01-17
JP6770946B2 (en) 2020-10-21
FR22C1058I1 (en) 2023-01-06
HUS2200054I1 (en) 2023-01-28
TW201613595A (en) 2016-04-16
AU2020200912A1 (en) 2020-02-27
CO2017000586A2 (en) 2017-06-20
SI3172209T1 (en) 2021-03-31
TWI724993B (en) 2021-04-21
US20170231997A1 (en) 2017-08-17
FR22C1058I2 (en) 2023-11-17
US10085993B2 (en) 2018-10-02
PE20170523A1 (en) 2017-05-17
CN115364061A (en) 2022-11-22
AU2021202500A1 (en) 2021-05-20
JP7002587B2 (en) 2022-01-20
EP3848376A1 (en) 2021-07-14
PT3172209T (en) 2021-02-11
TW202200148A (en) 2022-01-01
WO2016012963A1 (en) 2016-01-28
PL3172209T3 (en) 2021-06-14
CL2017000180A1 (en) 2017-09-15
ECSP17011672A (en) 2018-03-31
JO3618B1 (en) 2020-08-27
EA202191301A1 (en) 2021-11-30
MX2017001177A (en) 2017-05-01
JP2022046659A (en) 2022-03-23
CA2954840A1 (en) 2016-01-28
GT201700007A (en) 2018-12-18
AU2018207947A1 (en) 2018-08-09
ES2857523T3 (en) 2021-09-29
BR112017000953A2 (en) 2017-11-14
US20220249498A1 (en) 2022-08-11
AU2015293539A1 (en) 2017-02-02
US20210113569A1 (en) 2021-04-22
PH12017500121A1 (en) 2017-05-29
MX2021000595A (en) 2021-04-13

Similar Documents

Publication Publication Date Title
PH12019502810A1 (en) Bicyclic heterocycles as fgfr inhibitors
PH12016501139A1 (en) Bicyclic heterocycle compounds and their uses in therapy
MX2021000595A (en) Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl )imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide.
TW201613925A (en) Imidazopyrazines as LSD1 inhibitors
PH12016502291A1 (en) Indolizine derivatives as phosphoinositide 3-kinases inhibitors
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
PH12019500535A1 (en) 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof
MX2015013755A (en) Pharmaceutical formulation for use in the treatment and/or prevention of restenosis.
MX2017006513A (en) 1,9-diazaspiro undecane compounds having multimodal activity against pain.
ZA201704727B (en) New imidazo[1,2-a]quinoxalines and derivates thereof for the treatment of cancer
TH1701000365A (en) Flat tablet formulation of 2-fluoro-N-methyl-4-[7-(quinolin-6-ilmethyl)imidazo[1,2-b]. [1,2,4]Triacin-2-il]benzamide